Description: |
Amphotericin B is an antifungal agent. Amphotericin B can regulate inflammatory cytokines in host cells and regulate inflammatory responses in HGEC, it inhibits the A. actinomycetemcomitans-induced phosphorylation of ERK and p38 MAP kinase. Amphotericin B inhibits the A. actinomycetemcomitans-induced production of prostaglandin E2, the inhibition of the PKA signaling pathway can aid in reducing the degree of nephrotoxicity caused by Amphotericin B. Treatment with amphotericin B, particularly in combination with MCSF, increased the number of oligodendrocyte precursor cells and promoted remyelination within lesions. |
Targets: |
NO | PKA | IL Receptor | TNF-α | p38MAPK | ERK | PGE |
In vitro: |
Cell Immunol. 2014 Aug;290(2):201-8. | Amphotericin B down-regulates Aggregatibacter actinomycetemcomitans-induced production of IL-8 and IL-6 in human gingival epithelial cells.[Pubmed: 25064453] | Gingival epithelium is the primary barrier against microorganism invasion and produces inflammatory cytokines. Amphotericin B, a major antifungal drug, binds to cholesterol in the mammalian cell membrane in addition to fungal ergosterol. Amphotericin B has been shown to regulate inflammatory cytokines in host cells.
METHODS AND RESULTS:
To investigate the suppressive effect of Amphotericin B on the gingival epithelium, we examined the expression of interleukin (IL)-8 and IL-6 and involvement of MAP kinase in human gingival epithelial cells (HGEC) stimulated by Aggregatibacter actinomycetemcomitans. Amphotericin B and the p38 MAP kinase inhibitor down-regulated the A. actinomycetemcomitans-induced increase in the expression of IL-8 and IL-6 at the mRNA. The ERK inhibitor suppressed the A. actinomycetemcomitans-induced IL-8 mRNA expression. Amphotericin B inhibited the A. actinomycetemcomitans-induced phosphorylation of ERK and p38 MAP kinase. Furthermore, Amphotericin B inhibited the A. actinomycetemcomitans-induced production of prostaglandin E2.
CONCLUSIONS:
These results suggest that Amphotericin B regulate inflammatory responses in HGEC. |
|
In vivo: |
J Neurosci. 2015 Jan 21;35(3):1136-48. | Stimulation of monocytes, macrophages, and microglia by amphotericin B and macrophage colony-stimulating factor promotes remyelination.[Pubmed: 25609628] | Approaches to stimulate remyelination may lead to recovery from demyelinating injuries and protect axons. One such strategy is the activation of immune cells with clinically used medications, since a properly directed inflammatory response can have healing properties through mechanisms such as the provision of growth factors and the removal of cellular debris. We previously reported that the antifungal medication Amphotericin B is an activator of circulating monocytes, and their tissue-infiltrated counterparts and macrophages, and of microglia within the CNS. METHODS AND RESULTS: Here, we describe that Amphotericin B activates these cells through engaging MyD88/TRIF signaling. When mice were subjected to lysolecithin-induced demyelination of the spinal cord, systemic injections of nontoxic doses of Amphotericin B and another activator, macrophage colony-stimulating factor (MCSF), further elevated the representation of microglia/macrophages at the site of injury. Treatment with Amphotericin B, particularly in combination with MCSF, increased the number of oligodendrocyte precursor cells and promoted remyelination within lesions; these pro-regenerative effects were mitigated in mice treated with clodronate liposomes to reduce circulating monocytes and tissue-infiltrated macrophages.
CONCLUSIONS:
Our results have identified candidates among currently used medications as potential therapies for the repair of myelin. |
|